NGM120

BIOLOGICAL2 trials

Sponsors

Ngm Biopharmaceuticals Inc., NGM Biopharmaceuticals, Inc

Conditions

CachexiaColorectal Cancer with Cancer Cachexia

Phase 1

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

CompletedNCT03392116

NGM Biopharmaceuticals, IncCachexia

Start: 2018-01-29End: 2019-03-11Updated: 2019-08-20

Phase 2

A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia

Not yet recruitingCTIS2025-521730-28-00

Ngm Biopharmaceuticals Inc.Colorectal Cancer with Cancer Cachexia

Target: 54Updated: 2025-10-27